期刊文献+

HAND2在子宫内膜癌中的表达及意义

Expression and implication of HAND2 in endometrial carcinoma
下载PDF
导出
摘要 目的研究子宫内膜癌组织中心脏神经脊衍生物表达转录因子2(heart and neural crest derivatives-expressed transcript2,HAND2)的表达及意义。方法采用免疫组化方法检测86例子宫内膜样腺癌、30例子宫内膜不典型增生及28例正常子宫内膜组织中HAND2蛋白的表达情况并分析其与临床病理的关系。结果 HAND2蛋白在28例正常子宫内膜组织、30例子宫内膜不典型增生组织及86例子宫内膜样腺癌组织中的表达呈下降趋势(89.3%,60.0%,34.9%),HAND2蛋白在正常子宫内膜组织、子宫内膜不典型增生组织及子宫内膜样腺癌组织间的表达差异有统计学意义(P<0.05);HAND2蛋白在子宫内膜样腺癌组织中的表达与病理分期和肌层浸润有关(P<0.05),与组织学分级及淋巴结转移情况无关(P>0.05)。结论HAND2蛋白在子宫内膜样腺癌中表达下调可能与子宫内膜癌的发生发展有关。 Objective To investigate the expression and implication of HAND2 in endometrial carcinoma.Methods Expression of HAND2 was detected with immunohistochemistry SP assay in 28 cases of endometrial tissue,30 cases of atypical endometrial hyperplasia tissue and 86 cases of endometrial cancer,and its relationships with clinicopathological features were analyzed.Results The positive expression rate of HAND2 protein in endometrial cancer tissue was lower than that in endometrial tissue and atypical endometrial hyperplasia tissue(34.9% vs 89.3%,60.0%, P 〈0.05).The expression of HAND2 protein in endometrial cancer was related with pathological stage and myometrial invasion( P 〈0.05), but not with lymph node metastasis and pathological grading( P 〉0.05).Conclusion The downregulation of HAND2 protein expression in endometrial carcinoma may be related to the development of endometrial carcinoma.
作者 郭玉霞 GUO Yuxia(Department of Gynecology and Obstetrics,Second Affiliated Hospital of Jinan University Medical School,Shenzhen 518020,China)
出处 《山西医科大学学报》 CAS 2018年第9期1097-1099,共3页 Journal of Shanxi Medical University
关键词 HAND2 子宫内膜癌 免疫组化 HAND2 endometrial carcinoma immunohistochemistry
  • 相关文献

参考文献2

二级参考文献47

  • 1Salvesen HB, Stefansson I, Kretzschmar EI, et al. Significance of PTEN alterations in endometrial carcinoma: a population2based study of mutations, promote rmethylation and PTEN protein expression[J]. Int Oncol, 2004, 25 (6): 1615-1623.
  • 2Kovalenko TF, Vaniusheva OV, Shilov IA, et al. Promoters of genes MTHFR from patients with hyperhomocysteinemia and PTEN from patients with malignant and benign endometrial and ovarian tumors [J]. Bioorg Khim, 2006, 32(4): 414-423.
  • 3Semczuk A, Bohze C, Marzec B, et al. p16INK4A alterations are accompanied by aberrant protein immunostaining in endometrial carcinomas[J]. J Cancer Res Clin Oncol, 2003, 129 ( 10): 559-596.
  • 4Costa VL, Henrique R, Ribeiro FR, et al. Quantitative promoter methylatian analysis of multiple cancer-related genes in renal cell tumors[J]. BMC Cancer, 2007, 7: 133.
  • 5Pijnenborg J, Dam-de Veen G, Kisters N, et al. RASSF1A methylation and K-ras and B-raf mutations and recurrent endometrial cancer [J]. Ann Oncol, 2007, 18(3): 491-497.
  • 6Yanokura M, Banno K, Kawaguchi M, et al. Relationship of aberrant DNA hypermethylation of CHFR with sensitivity to taxanes in endometrial cancer[J] . Oncol Rep, 2007, 17( 1 ): 41-48.
  • 7Canlpan M, Weisenberger DJ, Laird PW, et al. DNA methylation profiles of female steroid hormone-driven human malignancies [J]. Curr Top Microbiol Ommunol, 2006, 310: 141-178.
  • 8Amant F, Moerman P, Neven P, et al. Endometrial cancer[J]. Lancet, 2005, 366 (9484): 491-505.
  • 9Esteller M. DNA methylation and cancer therapy: new developments and expectations[J]. Curt Oncol, 2005, 17( 1 ): 55-60.
  • 10Jin F, Dowdy SC, Xiong Y, et al. Up-regulation of DNA methyltransferase 3B expression in endometrial cancers [J ]. Gynecol Oncol, 2005, 96(2): 531-538.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部